Abstract
An increasing number of drugs removed from the market because of unacceptable toxicity raises concerns regarding preapproval testing of drug safety. In the present paper it is postulated that the non-inferiority type of trial should be abandoned in favor of the superiority trial with active controls and less stringent (p<0.1, both for efficacy and toxicity) statistics. This approach will increase sensitivity of detection of drug-induced adverse effects at the expense of increasing false positive results regarding the difference in efficacy between the tested and reference drug. Such a move will increase the protection of future patients. In addition, the proposed design is far more acceptable from the clinical (e.g. no need to specify the statistically expected “unimportant” number of deaths) and ethical points of view, as well as being favored by the strong incentive of involved parties. In the second part of this paper arguments are presented in favor of the hypothesis that placebo (still used in some superiority trials) does not induce adverse effects. The assertion that placebo may induce adverse effects is probably biased by the nature of the clinical experiment. Such a conclusion is supported by studies indicating that placebo-induced adverse effects are disease — and treatment — specific. The modification of clinical trials according to the proposed changes may increase the trials’ sensitivity at detecting adverse effects of drugs.
Similar content being viewed by others
References
Okie, S (2005) Safety in numbers — monitoring risk in approved drugs. The New England Journal of Medicine 352: 1173–1176.
Assche, Van G., Ranst, Van M., Sciot, F., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W. & Rutgeerts, P. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. The New England Jeournal of Medicine 353: 362–368.
Okie, S (2005) Raising the safety bar — the FDA’s Coxib Meeting. The New England Journal of Medicine 352:1283–1285.
Temple, R. & Ellenberg, S.S. (2000) Placebo controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133: 455–463.
Bombadier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K. & Schnitzer, T.J., for the VIGOR study group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine 343: 1520–1528.
Spławiński, J. & Kuźniar, J. (2004) Clinical trials: active control vs placebo — what is ethical ? Science and Engineering Ethics 10: 73–79.
Eisenberg, R.S. (2005) Learning the value of drugs — is rofecoxib a regulatory success story? The New England Journal of Medicine 352: 1285–1287.
Lin, Y.-L., Chern, H.-D. & Chu, M.-L. (2002) Placebo controlled clinical trials are as ethical as active controlled trials even if effective therapies exist. Drug Information Journal 36: 739–741.
Weihrauch, T. & Gauler, C. (1999) Placebo — efficacy and adverse effects in controlled clinical trials. Arzneim._Forsch./Drug Research 49: 385–393.
Weihrauch, T.R. (2004) Placebo treatment is effective differently in different stufdies — but is it also harmless ? A brief synopsis. Science and Engineering Ethics 10: 151–155.
Walach, H. (2003) Placebo and placebo effects — a concise review. Focus on Alternative and Complementary Therapies 8: 178–187.
Kaptchuk, T.J. (1998) Powerful placebo: the dark side of randomized controlled trial. The Lancet 351: 1722–1725.
Koch, A. & Rohmel, J. (2002) The impact of sloppy study to conduct on noninferiority studies. Drug Information Journal 36: 3–6.
Hrobjartsson, A. & Gotzsche, P.C. (2003) Is the placebo powerless? The New England Journal of Medicine 344: 1594–1602.
Leuchter, A.F., Cook, I.A. & White, E.A. (2002) Changes in brain function of depressed subject during treatment with placebo. American Journal of Psychiatry 159: 122–129.
Sher, L. (1997) The placebo effect on mood and behaviour: the role of the endogenous opioid system. Medical Hypotheses 48: 347–349.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spławiński, J., Kuźniar, J., Filipiak, K. et al. Evaluation of drug toxicity in clinical trials. SCI ENG ETHICS 12, 139–145 (2006). https://doi.org/10.1007/s11948-006-0014-y
Issue Date:
DOI: https://doi.org/10.1007/s11948-006-0014-y